Valneva announces publication of its chikungunya vaccine candidate phase 3 data in the lancet

Saint- herb lain (france ) , june 13 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announces that the company's pivotal phase 3 data for its single-shot chikungunya vaccine candidate, vla1553, have been published in the lancet , the world's leading peer-reviewed medical journal.
VALN Ratings Summary
VALN Quant Ranking